Open Nav

Please submit your session questions in advance at http://bit.ly/BIOCEO19question

Serina Therapeutics, Inc.

  • Randall Moreadith, Serina Therapeutics, Inc.

Serina Therapeutics, Inc. has developed a proprietary drug delivery polymer technology based upon the polymer poly(2-oxazoline), or POZ™. We are developing a pipeline of proprietary and partnered programs applying this platform to cancer, pain, refractory epilepsy, and movement disorders such as Parkinson’s disease and restless leg syndrome. In this presentation I will present "The Era of Once Weekly Continuous Drug Delivery in Parkinson's Disease is Here". We are launching a subsidiary focused on Parkinson's Disease and wish to meet with investors to raise a mezzanine round of $20-30 M with intent to IPO in 2019-2020.

  • Date:Monday, February 11
  • Time:9:15 AM - 9:30 AM
  • Room:Gramercy
  • Location:7th Floor
  • Session Type:Company Presentation
  • Please submit your session questions in advance:

    Click here.

  • Submission ID:23262
  • Company Presentation - Presentation Type:Privately Funded Company
  • Goal for Presentation:Attract investors
  • Company Website:www.serinatherapeutics.com
  • Company HQ City:Huntsville
  • Company HQ State:Alabama
  • Company HQ Country:United States
  • Total Amount Raised to Date, in All Rounds:$30 M
  • Size of Last Investment Round:$13 M
  • Previous and Current Investors:Approximately 50
  • CEO/Top Company Official:Randall W. Moreadith, MD, PhD
  • Year Founded:2007
  • Main Therapeutic Focus:CNS/Neurological
  • Lead Product in Development:SER-214
  • Development Phase of Primary Product:Phase II
  • Number Of Unlicensed Products (For Which You Are Seeking Partners):Three
  • Additional Information/Comments:Serina Therapeutics, Inc. has developed a proprietary drug delivery polymer technology based upon the polymer poly(2-oxazoline), or POZ™. We are developing a pipeline of proprietary and partnered programs : SER-214 - POZ-rotigotine, a once-weekly SC injection that is entering Phase II. SER-214 provides continuous drug delivery for Parkinson's disease and restless legs syndrome SER-240 - POZ-apomorphine, a SC injection in early pre-clinical development. SER-240 is designed to provide continuous drug delivery without the onerous side effects of current formulations of apomorphine. SER-240 will target advanced Parkinson's disease. SER-227 - POZ-buprenorphine, a one-time SC injection that can be delivered in the immediate post-operative period and provides 3-4 days of continuous delivery of buprenorphine. SER-227 is entering IND-enabling studies. SER-228 - POZ-cannabidiol, a weekly SC injection that delivers CBD continuously. SER-228 is being developed for refractory epilepsy.
Speakers
Randall Moreadith
Serina Therapeutics, Inc.
Back